<b>Background</b>: Pembrolizumab combined with pemetrexed-platinum chemotherapy is the standard first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 1-49%. The gene discussed is CD274; the disease is neoplasm.